|Bid||133.90 x 1800|
|Ask||134.00 x 1000|
|Day's range||130.30 - 134.14|
|52-week range||82.00 - 147.38|
|Beta (5Y monthly)||1.34|
|PE ratio (TTM)||10.44|
|Earnings date||04 Nov 2020 - 09 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||149.50|
Bristol Myers Squibb (NYSE: BMY), Baidu (NASDAQ: BIDU), and Morgan Stanley (NYSE: MS) are stocks that can give you some solid bang for your buck. Despite the bullishness around healthcare stocks this year (the Health Care Select Sector SPDR ETF is up 4% in 2020), there hasn't been much love thrown Bristol Myers Squibb's way. Bristol Myers Squibb has simply been out of the spotlight, and while that doesn't make it a bad stock, it does mean it's gotten lost amid all the hype.
Auto and tech giants are intensifying competition for driverless cars in the AV space, wherein Alphabet (GOOGL), Tesla (TSLA) and General Motors (GM) are the frontrunners.
Rosen Law Firm, a global investor rights law firm, reminds purchasers and those who otherwise acquired the securities of Baidu, Inc. (NASDAQ: BIDU) between April 8, 2016 and August 13, 2020, inclusive (the "Class Period"), of the important October 19, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Baidu investors under the federal securities laws.